Accelerate Diagnostics scheduled call to review 2021 fourth quarter and full year results

Rhea-AI Summary

Accelerate Diagnostics (NASDAQ: AXDX) announced a conference call scheduled for March 8, 2022, at 4:30 p.m. ET to discuss its 2021 fourth quarter and full year financial results. Investors can listen to the call via audio webcast or by phone, with a replay available until March 29, 2022. The company focuses on in vitro diagnostics, providing solutions to tackle antibiotic resistance and sepsis with its FDA-cleared Accelerate Pheno® system, which delivers faster antibiotic susceptibility results.

Positive

• The upcoming conference call will provide insights into the financial performance for Q4 and the full year of 2021.
• The Accelerate Pheno® system offers results 1 to 2 days faster than traditional methods, potentially increasing market competitiveness.
• The company's focus on antibiotic resistance and sepsis addresses critical global health issues.

Negative

• None.

TUCSON, Ariz., Feb. 24, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 8, 2022, at 4:30 p.m. Eastern Time to review 2021 fourth quarter and full year financial results.

To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until June 7, 2022.

To listen by phone, dial +1.877.883.0383 and enter the conference ID: 8732862. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 7365004 until March 29, 2022.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for serious infections. The FDA-cleared system and kit fully automate sample preparation steps, enabling phenotypic antibiotic susceptibility results in about 7 hours directly from positive blood cultures. Recent external studies indicate the solution offers results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient's infection, days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2021-fourth-quarter-and-full-year-results-301489272.html

SOURCE Accelerate Diagnostics, Inc.

FAQ

When is Accelerate Diagnostics' conference call to discuss fourth quarter results?

The conference call is scheduled for March 8, 2022, at 4:30 p.m. Eastern Time.

How can I access the Accelerate Diagnostics conference call?

You can listen to the conference call via audio webcast or by phone, with details provided in the press release.

What is the focus of Accelerate Diagnostics?

Accelerate Diagnostics focuses on in vitro diagnostics, specifically combating antibiotic resistance and sepsis.